On August 20, 2025 PharmaCyte Biotech, Inc. (Nasdaq:PMCB) ("PharmaCyte" or the "Company"), reported the closing of its previously announced $7 million financing (Press release, PharmaCyte Biotech, AUG 20, 2025, View Source [SID1234655409]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As of April 30, 2025, PharmaCyte had approximately $15.5 million in cash and also holds over $30 million of securities as reflected in the Company’s most recent 10K. With the addition of the $7 million in proceeds from this financing, the Company’s balance sheet has been further strengthened, providing significant financial flexibility to support its ongoing business initiatives and strategic growth opportunities.

"The successful completion of this financing is a welcome milestone as we continue on our growth trajectory," said Josh Silverman, Interim Chief Executive Officer of PharmaCyte. "We expect this additional capital, combined with our substantially reduced operational burn rate and our existing cash position and investments, to bring substantial value to our shareholders as we advance our initiatives and continue to evaluate opportunities that align with our long-term strategy."

As of the date of this release, PharmaCyte has approximately 6.8 million shares of common stock outstanding.